EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to iron and maintenance of normal hair growth pursuant to Article 13(5) of Regulation (EC) No 1924/2006

EFSA Publication; Tetens, Inge

Link to article, DOI: 10.2903/j.efsa.2012.2602

Publication date: 2012

Document Version
Publisher's PDF, also known as Version of record

Link back to DTU Orbit

Citation (APA):

DTU Library
Technical Information Center of Denmark

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
SCIENTIFIC OPINION

Scientific Opinion on the substantiation of a health claim related to iron and maintenance of normal hair growth pursuant to Article 13(5) of Regulation (EC) No 1924/2006

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)

European Food Safety Authority (EFSA), Parma, Italy

ABSTRACT

Following an application from Pierre Fabre Dermo-Cosmétique, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of France, the Panel on Dietetic Products, Nutrition and Allergies was asked to deliver an opinion on the scientific substantiation of a health claim based on newly developed scientific evidence related to iron and maintenance of normal hair growth. Iron is sufficiently characterised. The claimed effect is “reduction of excessive hair loss”. The target population proposed by the applicant is non-menopausal women, aged between 19 and 49 years, presenting with excessive hair loss. The Panel considers that maintenance of normal hair growth is a beneficial physiological effect. The applicant identified a total of five observational studies and one review as pertinent to the claim. In two observational studies no tests were performed to exclude individuals with raised serum ferritin owing to inflammation/infection. No conclusions could be drawn from these studies for the scientific substantiation of the claim. Two further observational studies provided no evidence for a relationship between iron status and hair loss while a third study showed an association between low iron status and hair loss. In weighing the evidence, the Panel took into account that two observational studies showed no association between iron status and hair loss while a third study showed an association. The Panel notes that these studies were not controlled for environmental and physiological factors which might have influenced iron status besides iron intake, or for factors other than iron status which might have influenced hair loss. The Panel concludes that a cause and effect relationship has not been established between the intake of iron and maintenance of normal hair growth. © European Food Safety Authority, 2012

KEY WORDS

Iron, hair growth, ferritin, health claims.

1 On request from the Competent Authority of France following an application by Pierre Fabre Dermo-Cosmétique, Question No EFSA-Q-2012-00059, adopted on 29 February 2012.

2 Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus Lovik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, Hildegard Pryzembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu

3 Acknowledgement: The Panel wishes to thank the members of the Working Group on Claims: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina Heinonen, Hannu Korhonen, Martinus Lovik, Ambroise Martin, Hildegard Pryzembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen for the preparatory work on this scientific opinion.

SUMMARY

Following an application from Pierre Fabre Dermo-Cosmétique, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of France, the Panel on Dietetic Products, Nutrition and Allergies was asked to deliver an opinion on the scientific substantiation of a health claim related to iron and maintenance of normal hair growth.

The scope of the application was proposed to fall under a health claim based on newly developed scientific evidence.

The food constituent that is the subject of the health claim is iron, formulated as ferrous sulphate. This evaluation applies to iron naturally present in foods and those forms authorised for addition to foods. The Panel considers that the food constituent, iron, which is the subject of the health claim, is sufficiently characterised.

The claimed effect is “reduction of excessive hair loss”. The target population proposed by the applicant is non-menopausal women, aged between 19 and 49 years, presenting with excessive hair loss. From the information provided, the Panel notes that the claimed effect relates to the maintenance of normal hair growth (i.e. reduced hair loss). The Panel considers that maintenance of normal hair growth is a beneficial physiological effect.

The applicant identified a total of five observational studies and one review as pertinent to the claim.

The narrative review contained no primary data and no conclusions could be drawn from this review for the scientific substantiation of the claim.

Five observational studies were presented; these investigated the relationship between low iron status in women and hair loss. It is noted that, while iron intake was not measured in those studies, iron status can be improved by increasing the intake of iron.

In two of the five observational studies, no tests were performed to exclude individuals with raised serum ferritin owing to inflammation/infection. The Panel considers that no conclusions can be drawn from these studies for the scientific substantiation of the claim.

In a cross-sectional observational study, hair loss (measured by trichogram) and serum ferritin concentrations were measured in 418 women aged 13-81 years. Individuals with abnormal biochemical results were excluded. The total number of women diagnosed with telogen effluvium was 135 and the mean ferritin concentration was 55.3 µg/L (range 2-304). No correlation was found between serum ferritin >10 µg/L and telogen hair loss rates. The Panel notes that this study provides no evidence for a relationship between iron status as measured by serum ferritin and hair loss.

In another cross-sectional observational study, serum ferritin and haemoglobin concentrations were measured in 30 women with telogen effluvium (aged 18-71 years) and compared with 11 women (aged 24-52 years) with no reported hair loss. Women with elevated erythrocyte sedimentation rate were excluded. The ferritin and haemoglobin concentrations in patients with telogen effluvium were not significantly lower than in controls. The Panel notes that this study provides no evidence for a relationship between iron deficiency and hair loss.

In a case-control study, serum ferritin concentrations of 30 women (aged 15-45 years) with diffuse telogen hair loss were compared with 30 women without hair loss (aged 15-45 years). Women with elevated erythrocyte sedimentation rate were excluded. Mean serum ferritin concentrations and transferrin saturation were significantly lower (p<0.001 and p=0.006, respectively) and total iron binding capacity was significantly higher (p=0.004) in the patients with telogen hair loss than controls. The odds ratio of having telogen hair loss was significantly higher in anaemic women.
Iron and maintenance of normal hair growth

(Hb <120 g/L) (10.5, 95 % CI 1.2-90.7, p=0.013) and in women with serum ferritin ≤30 ng/mL (21.0, 95 % CI 4.2-105.0, p<0.001). The Panel notes that this study shows an association between low iron status and hair loss. However, the Panel also notes that this cross-sectional study was not controlled for environmental and physiological factors which might have influenced iron status besides iron intake, or for factors other than iron status which might have influenced hair loss.

In weighing the evidence, the Panel took into account that two observational studies showed no relationship of iron status with hair loss and that one observational study showed an association. None of these studies was controlled for environmental and physiological factors which might have influenced iron status besides iron intake, or for factors other than iron status which might have influenced hair loss.

The Panel concludes that a cause and effect relationship has not been established between the intake of iron and maintenance of normal hair growth.
**TABLE OF CONTENTS**

Abstract .................................................................................................................................................... 1  
Summary .................................................................................................................................................. 2  
Table of contents .................................................................................................................................... 4  
Background ............................................................................................................................................... 5  
Terms of reference .................................................................................................................................. 5  
EFSA Disclaimer ...................................................................................................................................... 5  
Information provided by the applicant .................................................................................................... 6  
Assessment ............................................................................................................................................... 6  
1. Characterisation of the food/constituent .............................................................................................. 6  
2. Relevance of the claimed effect to human health ................................................................................. 7  
3. Scientific substantiation of the claimed effect ....................................................................................... 7  
Conclusions ............................................................................................................................................... 8  
Documentation provided to EFSA ........................................................................................................... 9  
References ............................................................................................................................................... 9
BACKGROUND

Regulation (EC) No 1924/2006\(^4\) harmonises the provisions that relate to nutrition and health claims, and establishes rules governing the Community authorisation of health claims made on foods. As a rule, health claims are prohibited unless they comply with the general and specific requirements of this Regulation, are authorised in accordance with this Regulation, and are included in the lists of authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this Regulation lays down provisions for the addition of claims (other than those referring to the reduction of disease risk and to children’s development and health) which are based on newly developed scientific evidence, or which include a request for the protection of proprietary data, to the Community list of permitted claims referred to in Article 13(3).

According to Article 18 of this Regulation, an application for inclusion in the Community list of permitted claims referred to in Art 13(3) shall be submitted by the applicant to the national competent authority of a Member State, which will make the application and any supplementary information supplied by the applicant available to the European Food Safety Authority (EFSA).

STEPS TAKEN BY EFSA

- The application was received on 30/12/2011.
- The scope of the application was proposed to fall under a health claim based on newly developed scientific evidence.
- The scientific evaluation procedure started on 20/01/2012.
- During its meeting on 29/02/2012, the NDA Panel, having evaluated the data submitted, adopted an opinion on the scientific substantiation of a health claim related to iron and maintenance of normal hair growth.

TERMS OF REFERENCE

EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an opinion on the scientific substantiation of a health claim related to: iron and maintenance of normal hair growth.

EFSA DISCLAIMER

The present opinion does not constitute, and cannot be construed as, an authorisation for the marketing of iron, a positive assessment of its safety, nor a decision on whether iron is, or is not, classified as a foodstuff. It should be noted that such an assessment is not foreseen in the framework of Regulation (EC) No 1924/2006.

It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006.

---

Iron and maintenance of normal hair growth

INFORMATION PROVIDED BY THE APPLICANT

Applicant’s name and address: Pierre Fabre Dermo-Cosmétique, Service Affaires Réglementaires, Hôtel Dieu - Toulouse, 2 rue Viguerie - BP 3071, 31025 Toulouse, France.

Food/constituent as stated by the applicant


Health relationship as claimed by the applicant

According to the applicant, iron is contained in porphyrins and particularly in haemoglobin, which transports oxygen to the tissues, including the hair follicles where oxygen is required for mitotic activity. The applicant further states that iron is an essential cofactor for ribonuclease reductase, which is involved in DNA synthesis. Thus, according to the applicant, iron deficiency might reduce the proliferation of hair follicle matrix cells, which might lead to an impaired hair growth and to an accelerated hair loss.

Wording of the health claim as proposed by the applicant

The applicant has proposed the following wording for the health claim: “excessive hair loss in non-menopausal women”.

Specific conditions of use as proposed by the applicant

The applicant has proposed a daily intake of 14 mg iron formulated as ferrous sulphate. The target population proposed by the applicant is non-menopausal women, aged between 19 and 49 years, presenting with excessive hair loss.

ASSESSMENT

1. Characterisation of the food/constituent

The food constituent that is the subject of the health claim is iron, formulated as ferrous sulphate.

Iron occurs naturally in foodstuffs in different oxidation states. The primarily occurring oxidation states in biological systems are +2 (ferrous state) and +3 (ferric state).


The Panel considers that the food constituent, iron, which is the subject of the health claim, is sufficiently characterised.

2. **Relevance of the claimed effect to human health**

The claimed effect is “reduction of excessive hair loss”. The target population proposed by the applicant is non-menopausal women, aged between 19 and 49 years, presenting with excessive hair loss.

From the information provided, the Panel notes that the claimed effect relates to the maintenance of normal hair growth (i.e. reduced hair loss).

The Panel considers that maintenance of normal hair growth is a beneficial physiological effect.

3. **Scientific substantiation of the claimed effect**

The applicant performed a literature search in Pubmed/Medline, Science Direct, IBIDS, Scirus, and Google Scholar, using the search terms “iron” or “ferrous sulphate/sulfate” or “iron sulphate/sulfate” and “hair” or “hair loss” or “hair follicle” or “hair shedding” or “hair density” or “trichogram”. Publications were included if they addressed the relationship between iron status and hair loss in women, comprising study populations presenting with telogen hair loss. Studies were excluded if they evaluated the effect of supplementation with iron combined with another substance, were carried out in women under 18 years or in people with alopecia areata and/or androgenic alopecia, or had a poor methodology (no study protocol, no information on iron dosage or study duration, small number of subjects). Review publications which did not provide any additional data were also excluded.

The applicant identified a total of five observational studies and one review as pertinent to the claim.

The narrative review (Trost et al., 2006) contained no primary data and no conclusions could be drawn from this review for the scientific substantiation of the claim.

Five observational studies were presented; these investigated the relationship between low iron status in women and hair loss. It is noted that, while iron intake was not measured in those studies, iron status can be improved by increasing the intake of iron.

In a case-control study, serum ferritin concentrations were measured in 72 women with chronic telogen effluvium hair loss and compared with 30 healthy controls (Obaidat et al., 2005). This comparison was followed by an intervention where the subjects with hair loss were given iron supplements but there was no control group in the intervention. In a cross-sectional study, serum ferritin was measured in 5110 women and hair loss was evaluated using a questionnaire (Deloche et al., 2007). Ferritin is an acute phase reactant; therefore serum concentrations increase in the presence of inflammation or infection and under these conditions serum ferritin cannot be used to measure iron status. No tests were performed in the above studies to exclude individuals with inflammation/infection. The Panel considers that no conclusions can be drawn from these studies for the scientific substantiation of the claim.

In a cross-sectional observational study (Brégny and Trüeb, 2008), hair loss (measured by trichogram) and serum ferritin concentrations were measured in 418 women (aged 13-81 years, mean 42). Individuals with abnormal biochemical results (e.g. C-reactive protein, thyroid function tests) were excluded. For the trichogram, at least 50 hairs were removed from two sampling sites and evaluation of different hair roots carried out based on morphological characteristics relating to the hair cycle. The total number of women diagnosed with telogen effluvium (with or without female pattern hair loss) was 135 and the mean ferritin concentration was 55.3 µg/L (range 2-304). No correlation was found between serum ferritin >10 µg/L and telogen hair loss rates. The Panel notes that this study provides no evidence for a relationship between iron status as measured by serum ferritin and hair loss.
In another cross-sectional observational study, 30 women with telogen effluvium (aged 18-71 years, mean 48) were recruited consecutively at a clinic, and serum ferritin and haemoglobin concentrations were measured and compared with 11 women (aged 24-52 years, mean 42) with no reported hair loss (Kantor et al., 2003). Women with elevated erythrocyte sedimentation rate, indicating non-specific inflammation that could increase serum ferritin, were excluded. The ferritin and haemoglobin concentrations in patients with telogen effluvium were not significantly different from the controls. The Panel notes that this study provides no evidence for a relationship between iron deficiency and hair loss.

In a case-control study, serum ferritin concentrations of 30 women (aged 15-45 years, mean 28) with diffuse telogen hair loss who attended a clinic between February 2005 and March 2006 were compared with 30 women without hair loss (aged 15-45 years, mean 29), recruited from the same clinic (Moeinvaziri et al., 2009). Women with elevated erythrocyte sedimentation rate were excluded. The women with hair loss were recruited consecutively but no details were given on how the control women were selected, apart from the fact that they had other (unspecified) dermatological problems. Patients were evaluated by a dermatologist to diagnose telogen hair loss by history (more than 100 hairs/day) and physical examination (more than 2 telogen hairs shed in light pull test). Mean serum ferritin concentration and transferrin saturation were significantly lower (p<0.001 and p=0.006, respectively) and total iron binding capacity was significantly higher (p=0.004) in the patients with telogen hair loss than controls. The odds ratio of having telogen hair loss was significantly higher in anaemic women (Hb <120 g/L) (10.5, 95% CI 1.2-90.7, p=0.013) and in women with serum ferritin ≤30 ng/mL (21.0, 95% CI 4.2-105.0, p<0.001). The Panel notes that this study shows an association between low iron status and hair loss. However, the Panel also notes that this cross-sectional study was not controlled for environmental and physiological factors which might have influenced iron status besides iron intake, or for factors other than iron status which might have influenced hair loss.

In weighing the evidence, the Panel took into account that two observational studies showed no relationship of iron status with hair loss and that one observational study showed an association. None of these studies was controlled for environmental and physiological factors which might have influenced iron status besides iron intake, or for factors other than iron status which might have influenced hair loss.

The Panel concludes that a cause and effect relationship has not been established between the intake of iron and maintenance of normal hair growth.

CONCLUSIONS

On the basis of the data presented, the Panel concludes that:

- The food constituent, iron, which is the subject of the health claim, is sufficiently characterised.
- The claimed effect is “reduction of excessive hair loss”. The target population proposed by the applicant is non-menopausal women, aged between 19 and 49 years, presenting with excessive hair loss. Maintenance of normal hair growth is a beneficial physiological effect.
- A cause and effect relationship has not been established between the intake of iron and maintenance of normal hair growth.
DOCUMENTATION PROVIDED TO EFSA


REFERENCES


